Articles

Original content brought to you by MedicalGold's team of analysts, leveraging over 30 years' capital markets expertise with deep industry knowledge to provide you with a unique perspective into the biotechnology sector and an edge in the investment arena.

Subscribe to Excellence

Welcome aboard! Your submission has been received and you are now a member of the MedicalGold.ca community.

Oops! Something went wrong while submitting the form. Please check the format of your entry.

Articles

Psychedelic Renaissance: Breakthrough Designations Confirm That The Era of Medical Psychedelics Is Upon Us

The Era Of Medical Psychedelics Is Upon Us

BioVaxys' Bargain Bonanza: Seizing a Biotech Treasure Trove from IMV's Ashes

Cancer Treatment Breakthrough Set to Print Cash (Repost)

3 Small Cap Biotech Stocks Poised For Big Moves In 2024

Psychedelic Breakthrough: Transforming Minds and Markets with Phase 2 Triumphs in Mental Health

It's Never Different This Time: The Psychology Of Market Cycles

CYB003: The Catalyst The Sector Has Been Waiting For.

Douglas Drysdale on Cybin's Psychedelic Breakthrough in Mental Health

Join MedicalGold in the Pursuit of Mental Health Breakthroughs at Wonderland Miami

Beyond the Bear: The Case For A Bright Horizon for Biotech in 2024

MedicalGold Co-Founder Robert Sinn (of Goldfinger Capital) Discusses Cybin and MindMed

The Psychedelic Surge: Steve Cohen’s Point72 Bets Big on Medical Psychedelics

Exclusive Interview With Doug Drysdale, CEO of Cybin, On The Future Of DMT

One Of Medical Gold's Biggest Winners In 2023 Is Setting Up For Its Next Upside Move

The Sunday Supplement: What's Moving Markets & Shaping The BioPharma Industry

Artificial Intelligence In Healthcare - Weekly Recap - August 2023

Revolutionizing Small Molecule Manufacturing: The AI/ML Paradigm Shift

In Search Of The Trading Holy Grail: Maximizing Profit Potential On Winning Trades

Improbable Allies Unite In Anticipation Of Imminent Ecstasy Legalization

FDA Approval For MDMA Is Coming Next Year: Here Are The 3 Companies Positioned To Profit Most

BREAKING: FDA Grants Conditional Approval To Sarepta's Gene Therapy For Duchenne Muscular Dystrophy

Canadian Insider Update: One Big Buyer And One Big Seller

Sarepta's Muscular Dystrophy Drug Gets Nod From FDA Advisors. Controversy Ensues.

Billionaire Hedge Fund Legend's Vision For The Changing World And Investing In The Next Crisis

Three Actionable Setups In Biotech And Medical Psychedelics

Medical Psychedelics Alert: These Two Psychedelic Leaders Are Making Headlines

Fed Announcement On Tap As System Risks Plunging Into Financial Whirlpool

MedicalGold's Canadian Top 5 Insider Buy List: Q1 2023

Buying $1.00 For $.50 On The Toronto Stock Exchange

The Rally Gains Steam: Biotech Is Significantly Outperforming The S&P

Top 5 Psychedelic Late-Stage Clinical Trials To Keep An Eye On in 2023 - (1H23 Update)

Psychedelics: From Woodstock to Walgreens - Updated (2023)

Microcap Biotech Rings In The New Year With HUGE Gains, The Seeds Of Despair Have Planted A New Bull Market

The Biotech Despair of 2022 Has Planted The Seeds For A Bull Market In 2023

MedicalGold's Canadian Top 5 Insider Buy List: Q4 2022

11 Ways To Avoid Losing Your Mind In The Digital Era

Beginner's Mind: A Powerful Place To Stand

The Biotech Resurrection: The Period of Biotech Outperformance Has Begun

Biotech Sector Forms A Double-Bottom | BioVaxys Shares Spike 60% On Heavy Volume

MedicalGold's Canadian Top 5 Insider Buy List: Q2 2022

A Dozen Risk Management Rules For Staying In The Game In Any Market Environment

Kevin O’Leary, Celebrity Shark Tank Investor, Calls Psychedelic Sector A "Once-In-A-Lifetime Opportunity"

MedicalGold's Canadian Top 5 Insider Buy List: Q1 2022

The Difference Between An Opinion And A Trade

Navigating Tumultuous Markets: 11 Lessons Learned Over Three Decades Of Trading

Managing Greed and Fear: The Biggest Secret To Trading Success

5 Industry Catalysts That Will Propel Psychedelics Into Mainstream Medicine

SARS-CoV-2 Origins, Immunology, and Treatments. Here’s What We Really Know About “The Science™” (PART III) - OMICRON edition

New Psychedelic Molecules: What’s in Development?

SARS-CoV-2 Origins, Immunology, and Treatments. Here’s What We Really Know About “The Science™” (PART II)

SARS-CoV-2 Origins, Immunology, and Treatments. Here’s What We Really Know About “The Science™” (PART I)

Pirates of the High-IP-Seas: Should The Government Exercise Its Rights To Commandeer Intellectual Property?

Biogen Wins Big! Now the FDA is Under Fire.

Psychedelic Sector Update: The Potential To Cure The Most Vexing Modern Mental Health Ailments

While The World Froze, Biotech Emerged The Hero We Needed: A Historic Year in R&D and Financing

Update on Biogen's "Aducanumab" - FDA Mandated Extended Review

Psychedelics: From Woodstock to Walgreens

What Does the FDA’s Meeting on Biogen’s Alzheimer Drug Teach Us?

MedicalGold's Biotech Terminology Index

COVID-19: A Misdirected Search for the Cure

FDA Approval Process, Pitfalls, & Keys to Success

Murders and Executions: Biotech Won't Stop Slayin'